Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12

Benzinga · 2d ago
Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.